<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230759</url>
  </required_header>
  <id_info>
    <org_study_id>RADIANCE</org_study_id>
    <secondary_id>2018-003005-25</secondary_id>
    <secondary_id>70113615</secondary_id>
    <secondary_id>ESR-17-13077</secondary_id>
    <nct_id>NCT04230759</nct_id>
  </id_info>
  <brief_title>Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group</brief_title>
  <acronym>RADIANCE</acronym>
  <official_title>Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goethe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a
      PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C
      (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced
      anal squamous cell carcinoma (ASCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world.
      There is a strong rationale for combining the PD-L1 immune checkpoint inhibitor durvalumab
      with radiochemotherapy (RCT) in patients with ASCC. First, although primary RCT with
      concurrent mitomycin C and 5-fluorouracil (MMC/5-FU) is the standard treatment for ASCC, the
      3-year DFS in patients with locally-advanced disease is only in the range of 60%. Second,
      approximately 80-90% of patients with ASCC are human papilloma virus (HPV)-positive, which is
      associated with higher tumor &quot;immunogenicity&quot; in this malignancy that is known to correlate
      with better response to RCT as well as PD-1/PD-L1 immune checkpoint inhibitors. Also, PD-L1
      expression was observed in 33%-62% of patients with locally advanced non-metastatic ASCC that
      correlated with tumor stage. Third, inhibition of the PD-1/PD-L1 axis showed encouraging
      responses in recurrent/metastatic ASCC in two phase Ib/II trials. Fourth, several data
      indicate complementary roles between R(C)T and immunotherapy. Fifth, R(C)T can induce PD-L1
      upregulation with resulting dysfunction in CD8+ T-cells, and addition of anti-PD-L1 to R(C)T
      can overcome T-cell suppression to reinvigorate immune surveillance. First clinical studies
      have demonstrated promising findings for the combination of RCT and immunotherapies. Thus,
      based on the above data, RCT combined with durvalumab is expected to be more effective than
      primary RCT alone. Altogether, the hereby proposed RADIANCE multicenter, randomized phase II
      trial aims to improve the current standard treatment by incorporating durvalumab to the
      primary MMC/5-FU-based RCT in patients with locally-advanced ASCC (T2=&gt;4cm Nany, stage
      IIB-IIIC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>DFS is defined as the time between randomization and the first of the following events: (a) non-complete clinical response at restaging MRI and proctoscopy, including biopsies of suspicious findings, 26 weeks after initiation of radiochemotherapy, (b) locoregional recurrence after initial complete clinical response (cCR), (c) distant metastases, (d) second primary cancer, or (e) death from any cause, whichever occurs first. Patients without any of these events are censored at the time point of last observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>3 Years</time_frame>
    <description>Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cCR</measure>
    <time_frame>26 weeks</time_frame>
    <description>Complete clinical response rate assessed 26 weeks after initiation of radiochemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 Years</time_frame>
    <description>Overall survival defined as the time between randomization and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colostomy-free survival</measure>
    <time_frame>3 Years</time_frame>
    <description>Colostomy-free survival defined as time between randomization and a definitive colostomy for progression, relapse, or complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of locoregional recurrence</measure>
    <time_frame>3 Years</time_frame>
    <description>Cumulative incidence of locoregional recurrence defined as the incidence of locoregional recurrence form the time of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of distant recurrence</measure>
    <time_frame>3 Years</time_frame>
    <description>Cumulative incidence of distant recurrence defined as the incidence of distant recurrence form the time of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>3 Years</time_frame>
    <description>Quality of life questionnaire QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>3 Years</time_frame>
    <description>Quality of life questionnaire QLQ-ANL27</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Anal Carcinoma</condition>
  <condition>Anal Cancer Stage III</condition>
  <condition>Anal Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>5FU+Mitomycin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiochemotherapy for anal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5FU+Mitomycin C+Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiochemotherapy with Durvalumab for anal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Patients recieve chemotherapy cycles as followed:
Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32</description>
    <arm_group_label>5FU+Mitomycin C</arm_group_label>
    <arm_group_label>5FU+Mitomycin C+Durvalumab</arm_group_label>
    <other_name>all brands of 5-fluorouracil (5-FU) are allowed</other_name>
    <other_name>all brands of Mitomycin C (MMC) are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>PTV_A (primary tumor): T1-T2&lt;4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2&gt;=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week</description>
    <arm_group_label>5FU+Mitomycin C</arm_group_label>
    <arm_group_label>5FU+Mitomycin C+Durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses</description>
    <arm_group_label>5FU+Mitomycin C+Durvalumab</arm_group_label>
    <other_name>PD-L1 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed ASCC (both genders) of the anal canal or the anal margin

          -  UICC-Stage IIB-IIIC including T2&gt;4cm Nany (IIB: T3N0M0; IIIA: T1-2N1M0; IIIB: T4N0M0;
             IIIC: T3-4N1M0; T2&gt;4cm Nany) according to proctoscopy, pelvic MRI, CT scan of thorax
             and abdomen, all within 30 days prior to recruitment

          -  Age ≥ 18 years, no upper age limit

          -  ECOG-Performance score 0-1

          -  History/physical examination within 30 days prior to recruitment

          -  Written informed consent and any locally-required authorization (e.g. EU Data Privacy
             Directive in the EU) obtained from the patient prior to performing any
             protocol-related procedures, including screening evaluations

          -  Life expectancy of &gt; 12 months

          -  Body weight &gt;30kg

          -  Hemoglobin ≥9.0 g/dl

          -  Leukocytes &gt;3.5 x 10 ^9/l

          -  Absolute neutrophil count (ANC) 1.5 x 10 9/l (&gt; 1500 per mm3)

          -  Platelet count ≥100 x 109/l (&gt;100,000 per mm3)

          -  Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). (This will not apply
             to patients with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed only in consultation with their physician.

          -  AST (SGOT), ALT (SGPT), AP ≤ 3x institutional ULN

          -  Calculated creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula creatinine clearance

          -  Female subject of childbearing potential should have a negative serum pregnancy within
             72 hours prior to receiving the first dose of durvalumab. A highly sensitive pregnancy
             test must be used.

          -  Female subjects of childbearing potential must be willing to use a highly effective
             contraceptive measure as defined in the Clinical Trial Facilitation Group (CTFG)
             guideline (&quot;Recommendations related to contraception and pregnancy testing in clinical
             trials&quot;). Highly effective contraception is required from screening to 90 days after
             the last dose of durvalumab. (Note: Abstinence is acceptable if this is the usual
             lifestyle and preferred contraception for the subject.)

          -  Male subjects of childbearing potential must agree to use a highly effective method of
             contraception, starting from screening to 90 days after the last dose of durvalumab.
             (Note: Abstinence is acceptable if this is the usual lifestyle and preferred
             contraception for the subject.) Male patients should refrain from fathering a child or
             donating sperm during the study and for 180 days after the last dose of durvalumab +
             any drug combination therapy or 90 days after the last dose of durvalumab monotherapy,
             whichever is the longer time period.

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

          -  For HIV-positive patients: running combined antiretroviral therapy (CART) on a stable
             dose at study entry and undetectable HIV-viral load (HIV Viral load &lt;50 copies/mL and
             CD4&gt;200/Mircoliter). Patients will be closely monitored and CART management will be
             performed according to appropriate labelling guidance of the antiviral therapy. CART
             should be on a stable dose at study entry.

        Exclusion Criteria:

          -  UICC-Stage I-IIA ASCC defined as cT1N0M0 or cT2 &lt;4cm N0M0 disease

          -  Second malignancy other than basalioma or cervical/genital/ neoplasia in situ

          -  History of another primary malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease ≥5 years
                  before the first dose of durvalumab and of low potential risk for recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  Known DPD-deficiency

          -  Participation in another clinical study with an investigational product during the
             last 12 months

          -  Concurrent enrolment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study

          -  Any previous treatment with other immunotherapy, a PD1 or PD-L1 inhibitor

          -  QT interval corrected for heart rate (QTc) ≥470 ms

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/d of
             prednisone, or an equivalent corticosteroid. In case of recent introduction of CART,
             inclusion will be possible provided subjects had at least 4 weeks of treatment prior
             to inclusion.

          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
             criteria:

               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after
                  consultation with the Study Chairman.

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with durvalumab may be included only after consultation with the Study
                  Chairman

          -  Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment, other
             than the study medication. Concurrent use of hormonal therapy for non-cancer-related
             conditions (e.g., hormone replacement therapy) is acceptable.

          -  Previous radiotherapy treatment to the pelvis or radiotherapy treatment to more than
             30% of the bone marrow or with a wide field of radiation within 4 weeks of the first
             dose of study drug

          -  Major surgical procedure (as defined by the Investigator) within 28 days prior to the
             first dose of durvalumab.

          -  History of allogenic organ transplantation.

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study chairman

               -  Patients with celiac disease controlled by diet alone

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring AEs or compromise the ability of the patient to give written
             informed consent

          -  History of leptomeningeal carcinomatosis or any other metastatic disease

          -  History of active primary immunodeficiency

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and TB testing in line with
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),
             hepatitis C. Patients with a past or resolved HBV infection (defined as the presence
             of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients
             positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction
             is negative for HCV RNA.

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of
             durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst
             receiving durvalumab and up to 30 days after the last dose of durvalumab.

          -  Known allergy or hypersensitivity to any of the study/investigational drugs or any of
             the study/investigational drug excipients and/or radiochemotherapy with 5-FU and
             Mitomycin C.

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanouil Fokas, Professor, MD, DPhil</last_name>
    <phone>+49 69 6301-5130</phone>
    <email>emmanouil.fokas@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Gollrad, Dr. med.</last_name>
      <phone>030-450627602</phone>
      <email>johannes.gollrad@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Axel Madlung, Dr. med.</last_name>
      <phone>030-450627602</phone>
      <email>axel.madlung@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Johannes Gollrad, Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel Madlung, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut für Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>. Christian Weiß, Prof. Dr.</last_name>
      <phone>+49 6151-1076851</phone>
      <email>Christian.Weiss@mail.klinikum-darmstadt.de</email>
    </contact>
    <contact_backup>
      <last_name>Christine Voith, Dr. med.</last_name>
      <phone>+49 6151-1076670</phone>
      <email>christine.voith@mail.klinikum-darmstadt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Weiß, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Voith, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Valentini</last_name>
      <phone>+49 351-4583352</phone>
      <email>Chiara.Valentini@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Christina Jentsch, Dr. med</last_name>
      <phone>+49 351-4583352</phone>
      <email>christina.Jentsch@ukdd.de</email>
    </contact_backup>
    <investigator>
      <last_name>Chiara Valentini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Jentsch, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Stuschke, Prof. Dr.</last_name>
      <phone>+49 201 7232320/21/22</phone>
      <email>martin.stuschke@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Pöttgen, Prof. Dr.</last_name>
      <phone>+49 201 72385085</phone>
      <email>christoph.poettgen@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Stuschke, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Pöttgen, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Goethe University Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanouil Fokas, Prof. Dr. Dr.</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>5130</phone_ext>
      <email>emmanouil.fokas@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Martin, Dr. med.</last_name>
      <phone>+49 69 6301</phone>
      <phone_ext>3742</phone_ext>
      <email>daniel.martin@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanouil Fokas, Prof. Dr. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Martin, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlenheilkunde, Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henning Schäfer, Dr. med.</last_name>
      <phone>+49 761-270-94060</phone>
      <email>henning.schaefer@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Simon Kirste, Dr. med.</last_name>
      <phone>+49 761-270-94010</phone>
      <email>simon.kirste@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Henning Schäfer, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Kirste, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Henkenberens, Dr. med.</last_name>
      <phone>0511-5322574</phone>
      <email>henkenberens.christoph@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Wichmann</last_name>
      <phone>Jörn</phone>
      <email>wichmann.joern@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christoph Henkenberens, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörn Wichmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RadioOnkologie und Strahlentherapie, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Debus, Prof. Dr.</last_name>
      <phone>06221-5638201</phone>
      <email>juergen.debus@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Koerber, Dr. med.</last_name>
      <email>stefan.koerber@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Debus, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Koerber, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Krug, Dr. med.</last_name>
      <phone>0431-50026501</phone>
      <email>David.krug@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Jürgen Dunst, Prof. Dr.</last_name>
      <phone>0431-50026501</phone>
      <email>juergen.dunst@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>David Krug, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Dunst, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Kuhnt, Prof.Dr.</last_name>
      <phone>0341-9718402</phone>
      <email>thomas.kuhnt@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Clemens Seidel, Dr.</last_name>
      <phone>0341-9718400</phone>
      <email>clemens.seidel@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Kuhnt, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Seidel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Brunner, Prof.Dr.</last_name>
      <phone>0391-6715791</phone>
      <email>thomas.brunner@med.ovgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Herbert Wördehoff, Dr.</last_name>
      <phone>0391-6713276</phone>
      <email>herbert.woerdehoff@med.ovgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Brunner, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herbert Wördehoff, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tilman Bostel, Dr. med.</last_name>
      <phone>06130-173851</phone>
      <email>tilman.bostel@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Heinz Schmidberger, Prof. Dr. med.</last_name>
      <phone>06130-173851</phone>
      <email>leitung-radioonkologie@unimedizin-mainz.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tilman Bostel, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heinz Schmidberger, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Engenhart-Cabillic, Prof. Dr.</last_name>
      <phone>064215866434</phone>
      <email>Rita.Engenhart-Cabillic@uk-gm.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Dumke</last_name>
      <phone>06421-5864690</phone>
      <email>Christoph.dumke@uk-gm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rita Engenhart-Cabillic, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Dumke</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Wündisch, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH Mönchengladbach</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Nestle, Prof.Dr.</last_name>
      <phone>02161 / 892-1801</phone>
      <email>ursula.nestle@mariahilf.de</email>
    </contact>
    <contact_backup>
      <last_name>Jochen Sistermanns, Dr.med.</last_name>
      <phone>02161 / 892-1860</phone>
      <email>jochen.sistermanns@mariahilf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ursula Nestle, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Sistermanns, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Belka, Prof.Dr.</last_name>
      <phone>089/4400-74521</phone>
      <email>claus.belka@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Walter, Dr.med.</last_name>
      <phone>089-440073770</phone>
      <email>franziska.walter@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Claus Belka, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franziska Walter, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Combs, Prof.Dr.</last_name>
      <phone>089 4140-4501</phone>
      <email>stephanie.combs@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Hendrik Dapper, Dr.med.</last_name>
      <phone>089 41409708</phone>
      <email>hendrik.dapper@mri.tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Combs, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrik Dapper, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Hautmann, Dr.med.</last_name>
      <phone>(0)941 944-7610</phone>
      <email>Matthias.Hautmann@klinik.uni-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Felix Steger, Dr.med.</last_name>
      <email>felix.steger@ukr.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Hautmann, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Steger, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Hildebrandt, Prof.Dr.</last_name>
      <phone>0381-494-9000</phone>
      <email>guido.hildebrandt@med.uni-rostock.de</email>
    </contact>
    <contact_backup>
      <last_name>Ute Küchenmeister, Dr.</last_name>
      <phone>0381-494-9030</phone>
      <email>ute.kuechenmeister@med.uni-rostock.de</email>
    </contact_backup>
    <investigator>
      <last_name>Guido Hildebrandt, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ute Küchenmeister, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cihan Gani, Dr.med.</last_name>
      <phone>07071-2968338</phone>
      <email>cihan.gani@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Zips, Prof.Dr.</last_name>
      <phone>07071-2982165</phone>
      <email>daniel.zips@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Cihan Gani, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Zips, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bülent Polat, Dr.</last_name>
      <phone>0931 201 28918</phone>
      <email>polat_b@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Marcus Zimmermann, Dr.med.</last_name>
      <phone>0931-20128291</phone>
      <email>Zimmermann_m@ukw.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bülent Polat, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcus Zimmermann, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Panagiotis Balermpas, PD Dr.med.</last_name>
      <phone>0041-44-2554204</phone>
      <email>panagiotis.balermpas@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Helena Garcia-Schüler, Dr.med.</last_name>
      <phone>0041-44-2559295</phone>
      <email>helena.garciaschueler@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Panagiotis Balermpas, PD Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Garcia-Schüler, Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Emmanouil Fokas</investigator_full_name>
    <investigator_title>Deputy Clinical Chair, Professor</investigator_title>
  </responsible_party>
  <keyword>Anal Cancer</keyword>
  <keyword>Anal Carcinoma</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>PD-L1 immune checkpoint inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

